The pediatric preclinical testing program: Description of models and early testing results

Pediatric Blood and Cancer

Volumn 49, Issue 7, 2007, Pages 928-940

  Houghton, Peter J ^a   Morton, Christopher L ^a   Tucker, Chandra ^a   Payne, Debbie ^a   Favours, Edward ^a   Cole, Claire ^a   Gorlick, Richard ^b   Kolb, E Anders ^b   Zhang, Wendong ^b   Lock, Richard ^c   Carol, Hernan ^c   Tajbakhsh, Mimi ^c   Reynolds, C Patrick ^d   Maris, John M ^e   Courtright, Joshua ^e   Keir, Stephen T ^g   Friedman, Henry S ^g   Stopford, Charles ^g   Zeidner, Joseph ^g   Wu, Jianrong ^a   Liu, Tiebin ^a   Billups, Catherine A ^a   Khan, Javed ^f   Ansher, Sherry ^f   Zhang, Jian ^f   Smith, Malcolm A ^f   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cyclophosphamide; Developmental therapeutics; Preclinical testing; Vincristine

Indexed keywords

CD45 ANTIGEN; CYCLOPHOSPHAMIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CONTROLLED STUDY; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; KIDNEY TUMOR; MEDULLOBLASTOMA; MOUSE; NEPHROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOID TUMOR; RHABDOMYOSARCOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; NEOPLASMS; TREATMENT OUTCOME; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34447249881     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21078     Document Type: Article

References (39)

1. Reis LA, Percy CL, Bunin GR. Cancer incidence and survival among children and adoloescents. United States SEER Program 1975-1995. NIH (Pub. No. 99-4649. Volume Introduction - SEER Pediatric Monograph. National Cancer Institute, Bethesda, MD; 1999. pp 1-15.
2. Ries LAG, Eisner MP, Kosary CL, et al. (eds). SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institiute; http://seer.cancer.gov/csr/1975_2002/.
3. Gurney JG, Young JL, Roffers SD, et al. Cancer incidence and survival among children and adolescents; United States SEER Program 1975-1995 NIH (Pub. 99-4649). National Cancer Institute, SEER Program 1999. 111-124.
4. Horowitz ME, Etcubanas E, Christensen ML, et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: A model for anticancer drug development. J Clin Oncol 1988;6:308-314.
5. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988;48:4189-4195.
6. Graham C, Tucker C, Creech J, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006;12:223-234.
7. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005;11:6950-6958.
8. Lock RB, Liem N, Farnsworth ML, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002;99:4100-4108.
9. Plowman J, Camalier R, Alley M, et al. US-NCI testing procedures. In: Feibig HH BA, editor. Relevance of tumor models for anticancer drug development. Basel: Karger; 1999. pp 121-135.
10. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-1431.
11. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-4239.
12. Bellet RE, Danna V, Mastrangelo MJ, et al. Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents. J Natl Cancer Inst 1979;63:1185-1188.
13. Boven E, Winograd B, Fodstad O, et al. Preclinical phase II studies in human tumor lines: A European multicenter study. Eur J Cancer Clin Oncol 1988;24:567-573.
14. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004;40:837-844.
15. Jimenez RE, Folpe AL, Lapham RL, et al. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: A clinicopathologic and immunohistochemical analysis of 11 cases. Am J Surg Pathol 2002;26:320-327.
16. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-122.
17. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-244.
18. Rosen G, Nirenberg A, Caparros B, et al. Osteogenic sarcoma: Eight-percent, three-year, disease-free survival with combination chemotherapy (T-7). Natl Cancer Inst Monogr 1981;56:213-220.
19. Sutow WW. Vincristine (NSC-67574) therapy for malignant solid tumors in children (except Wilms' tumor). Cancer Chemother Rep 1968;52:485-487.
20. Sutow WW, Vietti TJ, Fernbach DJ, et al. Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma. Cancer Chemother Rep 1971;55:67-78.
21. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004;103:3905-3914.
22. Bruheim S, Bruland OS, Breistol K, et al. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res 2004;10:133-141.
23. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A Pediatric Oncology Group study. Med Pediatr Oncol 1995;24:87-92.
24. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. J Clin Oncol 2002;20:426-433.
25. Rodriguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol 2002;24:250-255.
26. Berrak SG, Pearson M, Berberoglu S, et al. High-dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity. Pediatr Blood Cancer 2005;44:215-219.
27. Friedman HS, Bigner SH, Bigner DD. Cyclophosphamide therapy of medulloblastoma: From the laboratory to the clinic and back again (and again and again). J Neurooncol 1995;24:103-108.
28. Chamberlain MC, Tsao-Wei DD. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 2004;100:1213-1220.
29. Pierce M, Shore N, Sitarz A, et al. Cyclophosphamide therapy in acute leukemia of childhood. Cooperative study conducted by members of Children's Cancer Cooperative Group A. Cancer 1966;19:1551-1560.
30. Estlin EJ, Ronghe M, Burke GA, et al. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. Br J Haematol 2000;110:780-790.
31. Bell BA, Whitehead VM. Chemotherapy of childhood acute lymphoblastic leukemia. Dev Pharmacol Ther 1986;9:145-170.
32. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12:2607-2613.
33. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005;23:8819-8827.
34. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
35. Selawry OS, Holland JF, Wolman IJ. Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep 1968;52:497-500.
36. Sullivan MP, Nora AH, Kulapongs P, et al. Evaluation of vincristine sulfate and cyclophosphamide chemotherapy for metastatic neuroblastoma. Pediatrics 1969;44:685-694.
37. Bernstein ID, Evans AE, Finklestein J, et al. Phase II study of the failure of vincristine and bleomycin for previously treated children with metastatic neuroblastoma: A report from the Childrens Cancer Study Group. Cancer Treat Rep 1978;62:1201-1202.
38. Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 1997;8:313-322.
39. Zamboni WC, Stewart CF, Thompson J, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 1998;90:505-511.